Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies

T. Joseph Mattingly (), R. Brett McQueen and Pei-Jung Lin
Additional contact information
T. Joseph Mattingly: Patient-Driven Values in Healthcare Evaluation (PAVE) Center at the University of Maryland School of Pharmacy
R. Brett McQueen: University of Colorado Anschutz Medical Campus
Pei-Jung Lin: Tufts Medical Center

PharmacoEconomics, 2021, vol. 39, issue 10, No 1, 1107 pages

Abstract: Abstract The pipeline for new treatments for Alzheimer’s disease (AD) in the USA contains over 100 different agents, 80% of which can be categorized as disease-modifying therapies. The regulatory approval of the disease-modifying agent aducanumab has brought more attention to the complexity of the diagnosis, evaluation, and treatment of AD and the difficult decisions payers and policy makers will face over the next few years as innovation continues in this space. The value of AD treatment can vary widely according to the perspective of the analysis, sources of data, and methodological approach for the value assessment. This article focuses on AD-specific data gaps and measurement challenges and provides guidance for evidence generation to facilitate better value assessments for future AD treatments.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-021-01079-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:10:d:10.1007_s40273-021-01079-6

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-021-01079-6

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().